{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:38:24Z","timestamp":1790393904664,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical efficacy of maintenance therapy with sorafenib combined with interferon \u03b1-1b, interleukin-2, and thalidomide (the ITI regimen) in patients with FLT3-ITD-positive acute myeloid leukemia (AML).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>19 FLT3-ITD(+) AML patients were retrospectively analyzed, who received the sorafenib combined with ITI regimen as maintenance therapy after achieving remission at Affiliated Cancer Hospital of Zhengzhou University (January 2014\u2013December 2024). Minimal residual disease (MRD) levels were monitored, and clinical outcomes, including survival duration, were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study included 19 patients (9 males, 10 females) with a median age at diagnosis of 59 years (range: 21\u201376). The median white blood cell count was 32.25\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L (range: 0.7\u2013254\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L). Among them, 13 patients (68.4%) maintained sustained MRD negativity during sorafenib combined with TI regimen therapy, while 3 patients experienced morphological relapse and 3 had molecular relapse. Median overall survival (mOS) was not reached, with 12- and 24-month OS rates of 100% (19\/19) and 94.7% (18\/19), respectively. During maintenance therapy with sorafenib combined with ITI, median relapse-free survival (mRFS) was also not reached, with 12- and 24-month RFS rates of 73.7% (14\/19) and 57.9% (11\/19), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The sorafenib combined with ITI regimen is an effective maintenance therapy for FLT3-ITD (+) AML, significantly reducing relapse risk and prolonging survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1698935","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T05:20:14Z","timestamp":1762924814000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective analysis of sorafenib combined with interferon \u03b1-1b, interleukin-2, and thalidomide as maintenance therapy in FLT3-ITD-positive acute myeloid leukemia"],"prefix":"10.3389","volume":"15","author":[{"given":"Cheng","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100461","DOI":"10.1016\/j.xinn.2023.100461","article-title":"Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy","volume":"4","author":"Wang","year":"2023","journal-title":"Innovation (Camb)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281810","article-title":"Maintenance therapy in acute myeloid leukemia: advances and controversies","volume":"108","author":"Senapati","year":"2023","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000540","article-title":"Mutation- and MRD-informed treatments for transplant-ineligible patients","volume":"2024","author":"Lachowiez","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2022.130.","article-title":"How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication","volume":"6","author":"Perrone","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405098.","article-title":"Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway","volume":"22","author":"Zhang","year":"2008","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0663","article-title":"Sorafenib inhibition of mcl-1 accelerates ATRA-induced apoptosis in differentiation-responsive AML cells","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020301","article-title":"Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG","volume":"142","author":"Loo","year":"2023","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04621-w","article-title":"Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia","volume":"100","author":"Mi","year":"2021","journal-title":"Ann Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1426.2016.11.013","article-title":"Thalidomide combined with interferon and interleukin-2 in treatment of relapsed or refractory acute myelogenous leukemia","volume":"55","author":"Wei","year":"2016","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01389-2","article-title":"An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape","volume":"25","author":"Bystrom","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011582","article-title":"Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression","volume":"138","author":"Lv","year":"2021","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41408-023-00911-w","article-title":"Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors","volume":"13","author":"Short","year":"2023","journal-title":"Blood Cancer J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25198","article-title":"Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia","volume":"93","author":"Ohanian","year":"2018","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404508","article-title":"Antitumor activity of sorafenib in FLT3-driven leukemic cells","volume":"21","author":"Auclair","year":"2007","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/41048","article-title":"Effects of thalidomide combined with interferon on inhibiting kasumi-1 cell proliferation","volume":"25","author":"Xu","year":"2016","journal-title":"Adv Clin Exp medicine: Off Organ Wroclaw Med University"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101824","article-title":"Relapse prevention in acute myeloid leukemia: the role of immunotherapy with histamine dihydrochloride and low-dose interleukin-2","volume":"16","author":"Montesinos","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1097\/HS9.0000000000000159","article-title":"Maintenance therapy with interleukin-2 for childhood AML: results of ELAM02 phase III randomized trial","volume":"2","author":"Petit","year":"2018","journal-title":"HemaSphere"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2020.09.011","article-title":"Combination of interferon alpha-1b, interleukin-2 and thalidomide as maintenance therapy on acute myeloid leukemia patients with negative minimal residual disease","volume":"41","author":"Chen","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1698935\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T05:20:16Z","timestamp":1762924816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1698935\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":23,"alternative-id":["10.3389\/fonc.2025.1698935"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1698935","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"article-number":"1698935"}}